{"kzb3gYoAAAAJ": [["PACt-MD Study Group", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Andrea Weinstein", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Linda Mah", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Tarek Rajji", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["James Kennedy", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Benoit Mulsant", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Christopher Bowie", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Meryl Butters", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Alastair Flint", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Corinne Fischer", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Swathi Gujral", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Nathan Herrmann", 2020, "DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES"], ["Stephen H Pasternak", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["ONDRI Investigators", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Fuqiang Gao", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Tarek K Rajji", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Sean Symons", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Morris Freedman", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Miracle Ozzoude", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Sara Berman Mitchell", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Dallas Seitz", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Gary Naglie", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Christopher JM Scott", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Andrew Frank", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["David F Tang-Wai", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Carmela Tartaglia", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Michael Uri Wolf", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Richard H Swartz", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Joel Ramirez", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Sanjeev Kumar", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Bruce G Pollock", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["William Reichman", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Arunima Kapoor", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Corinne E Fischer", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Sandra E Black", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Nicolaas Paul LG Verhoeff", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Jennifer Mandzia", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Elizabeth Finger", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Michael Borrie", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Robert Bartha", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["Mario Masellis", 2020, "Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer\u2019s Disease Dementia: Findings from the Ontario Neurodegenerative \u2026"], ["J Kim", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["LC Quilty", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["P Gerretsen", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["Y Iwata", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["A Graff-Guerrero", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["S Dash", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["P Shah", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["F Caravaggio", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["BG Pollock", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["S Sockalingam", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["E Plitman", 2020, "DAS: The Diabetes Awareness and Insight Scale."], ["Yusuke Iwata", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Julia Kim", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Parita Shah", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Ariel Graff-Guerrero", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Philip Gerretsen", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Lena C Quilty", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Satya Dash", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Fernando Caravaggio", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Sanjeev Sockalingam", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Eric Plitman", 2020, "GAS: The Glycemia (Diabetes) Awareness and Insight Scale"], ["Jose Nobrega", 2020, "A cell-based assay and kits for assessing serum anticholinergic activity"], ["Roger Raymond", 2020, "A cell-based assay and kits for assessing serum anticholinergic activity"], ["W Mar", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["T Suzuki", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["S Nakajima", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["H Uchida", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["M Mimura", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["K Kusudo", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["BH Mulsant", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["DC Mamo", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["R Ochi", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["TK Rajji", 2019, "P. 181 Machine learning for classification of cognitive impairment according to antipsychotic dopamine receptor occupancy and illness severity in late-life schizophrenia"], ["Timothy A Allen", 2019, "A Hierarchical Integration of Normal and Abnormal Personality Dimensions: Structure and Predictive Validity in a Heterogeneous Sample of Psychiatric Outpatients"], ["Colin G DeYoung", 2019, "A Hierarchical Integration of Normal and Abnormal Personality Dimensions: Structure and Predictive Validity in a Heterogeneous Sample of Psychiatric Outpatients"], ["R Michael Bagby", 2019, "A Hierarchical Integration of Normal and Abnormal Personality Dimensions: Structure and Predictive Validity in a Heterogeneous Sample of Psychiatric Outpatients"], ["Karen Dagerman", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Jamie Perin", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Olga Brawman-Mintzer", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["DP Devanand", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Kim Martin", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Dave Shade", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Anne Shanklin Casper", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Maurcio Becerra", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Kyle Lago", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Jacobo Mintzer", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Hochang Lee", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Nimra Jamil", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Laura Simon-Pearson", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Constantine Frangakis", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Davangere P Devanand", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Andy Lears", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Milap Nowrangi", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Nancy Kowalski", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Paul B Rosenberg", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Gregory Pelton Jacobo Mintzer", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["David M Shade", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Benoit H Mulsant", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Nicholas Bienko", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Cynthia A Munro", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Lillian Lourenco", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Sarah Lawrence", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Paul Rosenberg", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Lea T Drye", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Lon S Schneider", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Melanie Keltz", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Anthony Awkar", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Sonia Pawluczyk", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Zahinoor Ismail", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Dimitri Avramopoulos", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Arthur Williams", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Susan Salem-Spencer", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Stephan Ehrhardt", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Alvin D McKelvy", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Kaitlyn Lane", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Liberty Teodoro", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Sheriza N Baksh", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Meghan Schultz", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Anton P Porsteinsson", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Jennifer Jones", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Sheriza Baksh", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Constantine G Lyketsos", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Asa Widman", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Laurie Ryan", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["Cynthia Munro", 2019, "Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial"], ["PACt\u2010MD Study Group", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Eric E Brown", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Aristotle N Voineskos", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Ariel Graff\u2010Guerrero", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Neda Rashidi\u2010Ranjbar", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Christopher R Bowie", 2019, "Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment"], ["Vincenzo De Luca", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Mahesh Menon", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Daniel M Blumberger", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Shinichiro Nakajima", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Gary Remington", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Youssef Alshehri", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Jun Ku Chung", 2019, "Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia"], ["Jyll Simmons", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Donna Kim", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Sarah Colman", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Amer M Burhan", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Simon Davies", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Amruta Shanbhag", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Saima Awan", 2019, "INTEGRATED CARE PATHWAY FOR AGITATION IN ALZHEIMER\u2019S DEMENTIA"], ["Angela Golas", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Wael K Karameh", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["David G Munoz", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Damien Gallagher", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Joseph Barfett", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Tom A Schweizer", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Ines Kortebi", 2019, "COGNITION AND CARDIOVASCULAR DISEASE BURDEN IN OLDER ADULTS WITH MAJOR DEPRESSIVE DISORDER AND MILD COGNITIVE IMPAIRMENT"], ["Reza Zomorrodi", 2019, "STUDYING THE EFFECTS OF REPETITIVE PAIRED ASSOCIATIVE STIMULATION ON DLPFC PLASTICITY AND MECHANISMS OF WORKING MEMORY IN ALZHEIMER\u2019S DISEASE USING TMS-EEG AND NBACK-EEG"], ["Heather Brooks", 2019, "STUDYING THE EFFECTS OF REPETITIVE PAIRED ASSOCIATIVE STIMULATION ON DLPFC PLASTICITY AND MECHANISMS OF WORKING MEMORY IN ALZHEIMER\u2019S DISEASE USING TMS-EEG AND NBACK-EEG"], ["Zafiris J Daskalakis", 2019, "STUDYING THE EFFECTS OF REPETITIVE PAIRED ASSOCIATIVE STIMULATION ON DLPFC PLASTICITY AND MECHANISMS OF WORKING MEMORY IN ALZHEIMER\u2019S DISEASE USING TMS-EEG AND NBACK-EEG"], ["Michelle S Goodman", 2019, "STUDYING THE EFFECTS OF REPETITIVE PAIRED ASSOCIATIVE STIMULATION ON DLPFC PLASTICITY AND MECHANISMS OF WORKING MEMORY IN ALZHEIMER\u2019S DISEASE USING TMS-EEG AND NBACK-EEG"], ["Adetunji Oremakinde", 2019, "S45. Working Memory Mediates the Association Between Dorsolateral Prefrontal Cortex Plasticity and Global Cognition in Alzheimer\u2019s Dementia and Healthy Comparison Individuals"], ["Pushpal Desarkar", 2019, "S45. Working Memory Mediates the Association Between Dorsolateral Prefrontal Cortex Plasticity and Global Cognition in Alzheimer\u2019s Dementia and Healthy Comparison Individuals"], ["Zafiris Daskalakis", 2019, "F3. Changes in Theta but not Alpha Modulation are Associated With Working Memory Impairments in Alzheimer\u2019s Dementia and Mild Cognitive Impairment"], ["Michelle Goodman", 2019, "F3. Changes in Theta but not Alpha Modulation are Associated With Working Memory Impairments in Alzheimer\u2019s Dementia and Mild Cognitive Impairment"], ["Mera Barr", 2019, "F3. Changes in Theta but not Alpha Modulation are Associated With Working Memory Impairments in Alzheimer\u2019s Dementia and Mild Cognitive Impairment"], ["Daniel Blumberger", 2019, "F3. Changes in Theta but not Alpha Modulation are Associated With Working Memory Impairments in Alzheimer\u2019s Dementia and Mild Cognitive Impairment"], ["Eric Brown", 2019, "S46. A Systematic Review of Case-Control Human Studies of Lead (Pb) in Alzheimer's Dementia"], ["Saba Shahab", 2019, "Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity"], ["David C Mamo", 2019, "Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity"], ["Marcos Sanches", 2019, "Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity"], ["Hiroyoshi Takeuchi", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Takashi Tsuboi", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Masaru Mimura", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Takefumi Suzuki", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Hiroyuki Uchida", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Robert R Bies", 2015, "Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study"], ["Gregory Pelton", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Christopher Marano", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["CitAD Research Group", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Jacobo E Mintzer", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Jerome Yesavage", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Peter V Rabins", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Curtis L Meinert", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Devangere P Devanand", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Daniel Weintraub", 2015, "Time to response to citalopram treatment for agitation in Alzheimer disease"], ["Simon JC Davies", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Barnett S Meyers", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Denise Sorisio", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Anthony J Rothschild", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Ellen M Whyte", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Alastair J Flint", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Margaret M Kirshner", 2015, "The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD"], ["Wanna Mar", 2015, "Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study"], ["Anne Leonpacher", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["Matthew E Peters", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["Kelly M Makino", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["Constantine Lyketsos", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["David Shade", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["Jeff Newell", 2015, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: Evidence from the citad study"], ["Sawsan M Kalache", 2015, "Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to N-Desmethylclozapine"], ["Christopher Tsoutsoulas", 2015, "Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to N-Desmethylclozapine"], ["Matthew Joseph", 2015, "Media depository"], ["Fredrik LN Kallin", 2015, "Media depository"], ["Joshua Bruce", 2015, "Media depository"], ["Robert Ross", 2015, "Media depository"], ["Ahmed Mezil", 2015, "Media depository"], ["Abhay Fernandez", 2015, "Media depository"], ["Julie A Schneider", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["Daniel Felsky", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["Jennie Pouget", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["William G Honer", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["James L Kennedy", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["Philip L De Jager", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["Romina Mizrahi", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["David A Bennett", 2015, "Translocator Protein (18kDa) rs6971 Is Associated with Markers of Cerebrovascular Disease and Neuroinflammation"], ["Robert Granger", 2015, "General Principles of Pharmacologic Therapy"], ["Aristotle Voineskos", 2015, "The Relationship Between Insight Into Illness and Cognition in Schizophrenia Across the Adult Lifespan"], ["Tarek Rajii", 2015, "The Relationship Between Insight Into Illness and Cognition in Schizophrenia Across the Adult Lifespan"], ["Jason P Lerch", 2015, "Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance"], ["M Mallar Chakravarty", 2015, "Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance"]]}